CAJ | 학술논문

肿瘤的发生、发展和治疗与机体免疫系统功能密切相关，伴随着肿瘤抗原、抗原呈递、T 细胞识别机制的突破性研究进展，研究者发现抗肿瘤多肽疫苗能够通过肿瘤抗原多肽识别抗原呈递细胞（antigen presenting cell ，APC）表面的主要组织相容性复合体（major histocompatibility complex ，M HC）分子，形成肽‐M HC‐T细胞受体（T cell receptor ，TCR）复合物，引起相应的细胞毒性 T 淋巴细胞（cytotoxic T lym‐phocyte ，CTL）免疫反应，从而杀伤肿瘤。因此，研制既能打破肿瘤患者存在的免疫耐受又能诱发针对肿瘤相关抗原（tumor‐associated antigen ，TAAs）特异性免疫应答的高效多肽疫苗已成为肿瘤免疫治疗研究的热点。文章综述了肿瘤多肽疫苗抗肿瘤相关机制及其在该领域所取得的最新临床研究进展。
종류적발생、발전화치료여궤체면역계통공능밀절상관，반수착종류항원、항원정체、T 세포식별궤제적돌파성연구진전，연구자발현항종류다태역묘능구통과종류항원다태식별항원정체세포（antigen presenting cell ，APC）표면적주요조직상용성복합체（major histocompatibility complex ，M HC）분자，형성태‐M HC‐T세포수체（T cell receptor ，TCR）복합물，인기상응적세포독성 T 림파세포（cytotoxic T lym‐phocyte ，CTL）면역반응，종이살상종류。인차，연제기능타파종류환자존재적면역내수우능유발침대종류상관항원（tumor‐associated antigen ，TAAs）특이성면역응답적고효다태역묘이성위종류면역치료연구적열점。문장종술료종류다태역묘항종류상관궤제급기재해영역소취득적최신림상연구진전。
It's well known that the immune system is closely related to the genesis ,progression and clinical response of the tumor .With the breakthrough development of the research on tumor antigen ,antigen pres‐entation and T cell recognition mechanism ,antitumor peptide vaccine can produce the Peptide‐M HC‐T cell receptor (TCR) complex by delivering the tumor antigen to the major histocompatibility complex (M HC) of antigen presenting cell (APC) ,causing cytotoxic T lymphocyte (CTL) response ,which can kill tumor cells .It has became the keen point on the tumor immunotherapy to develop the efficient peptide vaccines that may ow n the capacity of breaking immunological tolerance and eliciting tumor‐associated antigen (T A‐As)‐specific immunity in a majority of patients .This article reviewed how antitumor peptide vaccine had occurred and developed ,adding to the latest clinical research progress in this field .